qtrly call, page-5

I suggest a few of you re read this - you have somethings mixed up.

Good afternoon - and good morning to those in Australia.

· Before we discuss the quarter, I’m excited to tell you that we are getting ready to announce our first major long-term supply contract for the Unifill syringe.

· This is a significant multi-year commercial supply contract with a major pharmaceutical customer that generates revenue immediately.

· The negotiations for this agreement are complete. All terms have been agreed upon. The execution copy is being routed for signature by both parties.

· This agreement will establish Unilife as one of the leading suppliers of prefilled syringes in our industry. It also reaffirms all aspects of our business model.

· We are scheduling a press conference in New York City to make the formal announcement in the next couple of weeks.

· This is the first in a series of significant revenue-generating contracts that are ready to emerge from our commercial pipeline.

· Revenue associated with these agreements will be recognized from the July quarter onwards.

· I have always said that 2013 was going to be the inflection point for our business. I am very pleased that we have turned the corner.

· We are now entering a period of hyper-growth that will progressively build through fiscal year 2014 and beyond.

· I expect that over the coming year, you will see the focus of our public discussions begin to shift from the commercial pipeline to our financials and business growth.

· We therefore plan to begin providing guidance some time during fiscal 2014.

· This guidance will provide greater clarity to analysts and investors on our business trajectory and the revenue generated by these long-term contracts.

· This supply contract for Unifill is the second in a series of agreements that we expect to announce and generate immediate revenue from.

· The first of these agreements was announced last month – a15 year customization and commercial supply contract for the EZMix dual-chamber syringe that will generate up to $110 million in cumulative revenue.

· I consider that some of the additional agreements announced over the coming months will be of an even greater magnitude.

· Given the significance and quantum value of what’s being negotiated, it is important that we take the time to ensure each agreement delivers maximum benefits for our shareholders.

· In some cases, customers are targeting our products for an entire portfolio of their injectable drugs. Other customers are targeting our products for high value drugs as part of a lifecycle management strategy to defend market share against branded, biosimilar or generic competition.

· These upcoming agreements encompass all products in our broad portfolio of injectable drug delivery systems.

· “With so many transformational agreements generating immediate revenue, we have no intention of doing any secondary stock offering that would cause significant dilution to existing shareholders.

· We have therefore agreed to terms with a major U.S. life-science financing firm for a debt funding program which we expect to finalize later this month.

· This program sufficiently strengthens our balance sheet during this period in which we transition towards strong and accelerating revenue growth.

· I would now like to hand the call over to our CFO Rich Wieland to walk us through the fiscal year third quarter results.